Skip to main content

Dow jumps 300 points as Wall Street tries to end a strong first half on a high note: Live updates

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with...
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – c...
Post a Comment
Read More

Biotech, pharma M&A is off to a good start in 2025 — but will it last?

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 21, 2025 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Happy Tuesday! I'm back in New York City after spending nearly a week in San Francisco for the annual JPMorgan Health Care Conference – the largest gathering in the U.S. of biotech and pharma execs, investors and analysts (and health reporters, of course).  The week featured questions about the incoming Trump administration, updates on business outlooks and drug portfolios, heightened security on the ground and, for the first time in recent memory, sunny weather in San Francisco.  The news kept coming all week, even after the conference ended mid-Thursday. The Biden administration on Friday announced the next 15 drugs included in Medicare price negotiations, which include Novo Nordisk's blockbuster diabetes drug Ozempic and its obesity counterpart Wegovy.  But after companies ann...
Post a Comment
Read More